At the time of writing, Tscan Therapeutics Inc [TCRX] stock is trading at $1.21, up 2.54%. An important factor to consider is whether the stock is rising or falling in short-term value. The TCRX shares have gain 18.63% over the last week, with a monthly amount glided 19.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tscan Therapeutics Inc [NASDAQ: TCRX] stock has seen the most recent analyst activity on November 14, 2025, when Morgan Stanley downgraded its rating to a Equal-Weight. Previously, BTIG Research started tracking the stock with Buy rating on May 16, 2024, and set its price target to $12. On May 13, 2024, Needham initiated with a Buy rating and assigned a price target of $11 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $8 on June 22, 2023.
For the past year, the stock price of Tscan Therapeutics Inc fluctuated between $0.88 and $2.85. Currently, Wall Street analysts expect the stock to reach $7.5 within the next 12 months. Tscan Therapeutics Inc [NASDAQ: TCRX] shares were valued at $1.21 at the most recent close of the market. An investor can expect a potential return of 519.83% based on the average TCRX price forecast.
Analyzing the TCRX fundamentals
According to Tscan Therapeutics Inc [NASDAQ:TCRX], the company’s sales were 8.42M for trailing twelve months, which represents an 139.37% jump. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -20.72%, Pretax Profit Margin comes in at -19.65%, and Net Profit Margin reading is -19.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.64 and Total Capital is -0.54. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Tscan Therapeutics Inc [NASDAQ:TCRX] has a current ratio of 6.44. On the other hand, the Quick Ratio is 6.44, and the Cash Ratio is 5.41. Considering the valuation of this stock, the price to sales ratio is 7.95, the price to book ratio is 0.48.
Transactions by insiders
Recent insider trading involved Lynx1 Capital Management LP, 10% Owner, that happened on Dec 19 ’25 when 80069.0 shares were purchased. 10% Owner, Lynx1 Capital Management LP completed a deal on Dec 22 ’25 to buy 75500.0 shares. Meanwhile, 10% Owner Lynx1 Capital Management LP bought 6232.0 shares on Dec 23 ’25.
